Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,179.37
+10.56 (+0.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
33
34
Next >
Our 7 Top Biotech Stock Picks for 2023
December 09, 2022
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.
Via
InvestorPlace
Will This Potential Approval Be a Winner for Sanofi's Shareholders?
December 09, 2022
Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union.
Via
The Motley Fool
Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed
December 08, 2022
Read the latest report on Sunshine Biopharma here.
Via
Benzinga
Can These 2 Stocks Crush the Market Again in 2023?
December 04, 2022
Both are riding the wave of major clinical wins
Via
The Motley Fool
Regeneron's Evkeeza Under FDA Priority Review For Younger Kids With Inherited Form Of High Cholesterol
November 30, 2022
Via
Benzinga
CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron
November 17, 2022
Via
Benzinga
Regeneron Pharmaceuticals's Return On Capital Employed Overview
November 17, 2022
Via
Benzinga
Regeneron Pharmaceuticals Tops Quarterly Expectations Despite Covid Shortfall
November 03, 2022
Excluding the year-earlier impact of the Covid drug, third-quarter sales grew 11%.
Via
Investor's Business Daily
UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent
November 30, 2022
Via
Benzinga
2 Market-Beating Stocks That Can Continue Rising in 2023
November 30, 2022
It's not too late to get in on the potential 2023 growth for these two stocks.
Via
The Motley Fool
Market Currents: Why Pick Stocks?
November 28, 2022
Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and...
Via
Talk Markets
Stock Market Investing Action Plan: What Part Of November Don't You Understand?
November 25, 2022
A turnabout month left the market sitting on some nice gains. The next week's data might determine whether those gains hold.
Via
Investor's Business Daily
Dexcom Leads 5 Stocks Near Buy Points
November 25, 2022
They combine strong technicals and generally sound fundamentals.
Via
Investor's Business Daily
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
November 18, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough."
Via
Benzinga
Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?
November 17, 2022
CytomX Therapeutics (CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (REGN).
Via
InvestorPlace
Daily Stock Analysis: Sanofi - November 2022 Snapshot
November 16, 2022
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company's decided in late 2019 to pull back from the cardio-metabolic...
Via
Talk Markets
2 Top Biotech Stocks to Buy in November
November 12, 2022
Both of these companies have potential catalysts on the way.
Via
The Motley Fool
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
November 10, 2022
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen.
Via
Investor's Business Daily
$100 Invested In This Stock 15 Years Ago Would Be Worth $4,000 Today
November 10, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.17% on an annualized basis producing an average annual return of 27.88%. Currently, Regeneron...
Via
Benzinga
7 Cash-Rich Stocks to Buy for Peace of Mind
November 04, 2022
It pays to hold cash-rich stocks that can weather any storm because of their financial strength. Investors may want to watch these seven.
Via
InvestorPlace
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review
November 04, 2022
A mixed jobs report and heavy earnings swung stocks.
Via
Investor's Business Daily
Regeneron Pharmaceuticals: Q3 Earnings Insights
November 03, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
November 02, 2022
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange...
Via
Benzinga
Here's How Much $1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
November 02, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.24% on an annualized basis producing an average annual return of 27.82%. Currently, Regeneron...
Via
Benzinga
Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a ‘Blue Wave’
October 27, 2022
If you see a blue wave coming get out of the oilpatch, crypto, and pharmaceuticals that are subject to price regulation.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
October 26, 2022
Upgrades
Via
Benzinga
Earnings Scheduled For November 3, 2022
November 03, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
October 25, 2022
The company hopes to come out next year with at least one heart-failure drug.
Via
Investor's Business Daily
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
October 25, 2022
Biosimilars are bringing down prescription drug costs without sacrificing quality.
Via
The Motley Fool
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.